Investment analysts at Bank of America initiated coverage on shares of Finch Therapeutics Group (NASDAQ:FNCH) in a report released on Monday, Benzinga reports. The brokerage set a “buy” rating and a $25.00 price target on the stock. Bank of America‘s price target indicates a potential upside of 75.69% from the company’s current price.
Several other equities analysts have also commented on the stock. Jefferies Financial Group started coverage on shares of Finch Therapeutics Group in a research report on Monday. They set a “buy” rating and a $29.00 price target for the company. Evercore ISI started coverage on shares of Finch Therapeutics Group in a research report on Monday. They set an “outperform” rating and a $34.00 price target for the company.
Finch Therapeutics Group stock opened at $14.23 on Monday. Finch Therapeutics Group has a one year low of $13.94 and a one year high of $22.50.
Finch Therapeutics Group Company Profile
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, engages in developing a novel class of orally administered biological drugs in the United States. Its lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection.
Recommended Story: Stop Order
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.